Lindbrook Capital LLC Purchases 250 Shares of Elevance Health, Inc. (NYSE:ELV)

Lindbrook Capital LLC increased its position in shares of Elevance Health, Inc. (NYSE:ELV) by 72.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 595 shares of the company’s stock after acquiring an additional 250 shares during the period. Lindbrook Capital LLC’s holdings in Elevance Health were worth $281,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. International Assets Investment Management LLC boosted its position in shares of Elevance Health by 45,888.1% during the 4th quarter. International Assets Investment Management LLC now owns 255,694 shares of the company’s stock valued at $1,205,750,000 after purchasing an additional 255,138 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in shares of Elevance Health by 212.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 366,833 shares of the company’s stock valued at $159,726,000 after purchasing an additional 249,533 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec boosted its position in shares of Elevance Health by 57.7% during the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 640,905 shares of the company’s stock valued at $279,063,000 after purchasing an additional 234,439 shares in the last quarter. Schroder Investment Management Group boosted its holdings in Elevance Health by 18.2% in the third quarter. Schroder Investment Management Group now owns 1,330,883 shares of the company’s stock worth $579,493,000 after acquiring an additional 204,715 shares in the last quarter. Finally, Qube Research & Technologies Ltd boosted its holdings in Elevance Health by 59.3% in the third quarter. Qube Research & Technologies Ltd now owns 491,504 shares of the company’s stock worth $214,011,000 after acquiring an additional 182,889 shares in the last quarter. Institutional investors own 89.24% of the company’s stock.

Analyst Ratings Changes

ELV has been the topic of several recent research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $580.00 price target on shares of Elevance Health in a report on Wednesday, April 10th. UBS Group increased their price target on Elevance Health from $585.00 to $605.00 and gave the stock a “buy” rating in a report on Friday. Barclays increased their price target on Elevance Health from $584.00 to $621.00 and gave the stock an “overweight” rating in a report on Friday. Wells Fargo & Company raised their target price on Elevance Health from $557.00 to $600.00 and gave the company an “overweight” rating in a report on Friday. Finally, Jefferies Financial Group raised their target price on Elevance Health from $602.00 to $604.00 and gave the company a “buy” rating in a report on Friday. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $587.64.

Insider Activity

In other news, Director Ramiro G. Peru sold 753 shares of Elevance Health stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $500.00, for a total value of $376,500.00. Following the completion of the transaction, the director now directly owns 9,109 shares in the company, valued at $4,554,500. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.29% of the stock is owned by company insiders.

Elevance Health Stock Performance

NYSE:ELV opened at $532.17 on Tuesday. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.37 and a quick ratio of 1.37. The business has a fifty day simple moving average of $509.68 and a two-hundred day simple moving average of $484.51. Elevance Health, Inc. has a 1 year low of $412.00 and a 1 year high of $539.11. The company has a market capitalization of $123.69 billion, a P/E ratio of 20.11, a P/E/G ratio of 1.16 and a beta of 0.78.

Elevance Health (NYSE:ELV) last released its earnings results on Thursday, April 18th. The company reported $10.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.54 by $0.10. Elevance Health had a return on equity of 20.62% and a net margin of 3.64%. The business had revenue of $42.27 billion during the quarter, compared to the consensus estimate of $42.49 billion. During the same period last year, the business posted $9.46 earnings per share. The business’s revenue for the quarter was up .9% on a year-over-year basis. On average, analysts expect that Elevance Health, Inc. will post 37.24 earnings per share for the current year.

Elevance Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 25th. Stockholders of record on Monday, June 10th will be given a $1.63 dividend. This represents a $6.52 annualized dividend and a dividend yield of 1.23%. The ex-dividend date is Monday, June 10th. Elevance Health’s dividend payout ratio (DPR) is presently 24.64%.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.